Global Regenerative Medicine Market 2024-2028
The regenerative medicine market is forecasted to grow by USD 70110.07 mn during 2023-2028, accelerating at a CAGR of 23.31% during the forecast period. The report on the regenerative medicine market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of chronic diseases, increasing support from public and private healthcare organizations, and increasing adoption of stem cell therapy.
Technavio's regenerative medicine market is segmented as below:
By Application
- Oncology
- Musculoskeletal
- Dermatology
- Immunology and inflammation and others
By Technology
- Cell
- tissue-based
- Gene therapy
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the increasing number of clinical trials as one of the prime reasons driving the regenerative medicine market growth during the next few years. Also, emerging technological advances in global regenerative medicine market and increasing prominence of chimeric antigen receptor t-cell (CAR-T) therapies will lead to sizable demand in the market.
The report on the regenerative medicine market covers the following areas:
- Regenerative medicine market sizing
- Regenerative medicine market forecast
- Regenerative medicine market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading regenerative medicine market vendors that include AbbVie Inc., Amgen Inc., Baxter International Inc., Becton Dickinson and Co., Cook Group Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Integra Lifesciences Corp., Johnson and Johnson, Medtronic Plc, Merck and Co. Inc., Mesoblast Ltd., MiMedx Group Inc., Novartis AG, Nuvasive Inc., Organogenesis Holdings Inc., Smith and Nephew plc, Thermo Fisher Scientific Inc., Vericel Corp., and Zimmer Biomet Holdings Inc.. Also, the regenerative medicine market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.